

Figure 1




Figure 2





Figure 3






Figure 4




Figure 5

Figure 6




Figure 7




Figure 8





Figure 9







Figure 11






Figure 12

Figure 13




Figure 14





Figure 15



16/155

Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24




Figure 25





Figure 26






Figure 29




Figure 30




Figure 31




Figure 32




Figure 33




Figure 34






Figure 35




36/155

Figure 36a



37/155

Figure 36b



38/155

Figure 37




Figure 37 (continued)





Figure 38



41/155

Figure 39




Figure 40




Figure 41




Figure 42





Figure 43



46/155




Figure 44




Figure 45

Figure 46






Figure 47



50/155

Figure 48


Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Safety Population – Stage 1, 2 Dose, 21 Days Apart – 18-55 Years of Age – BNT162b1



Note: Number above each bar denotes percentage of participants reporting the event with any severity.


Figure 49

Systemic Events, by Maximum Severity, Within 7 Days After Each Dose – Safety Population – Stage 1, 2 Dose, 21 Days Apart – 18-55 Years of Age – BNT162b1




Note: Severity was not collected for use of antipyretic or pain medication.
Note: Number above each bar denotes percentage of participants reporting the event with any severity.

Figure 50



Note: Dot presents individual antibody levels.
Note: Number within each bar denotes geometric mean.

Figure 51




Note: Dot presents individual antibody levels.
Note: Number within each bar denotes geometric mean.

54/155

Figure 52

Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Safety Population – Stage 1, 2 Dose, 21 Days Apart – 18-55 Years of Age – BNT162b2




Note: Number above each bar denotes percentage of participants reporting the event with any severity.

55/155

Figure 53

Systemic Events, by Maximum Severity, Within 7 Days After Each Dose – Safety Population – Stage 1, 2 Dose, 21 Days Apart – 18-55 Years of Age – BNT162b2




Note: Severity was not collected for use of antipyretic or pain medication.
Note: Number above each bar denotes percentage of participants reporting the event with any severity.

56/155

Figure 54


Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Safety Population –
Stage 1, 2 Dose, 21 Days Apart – 65-85 Years of Age – BNT162b2



Note: Number above each bar denotes percentage of participants reporting the event with any severity.


Figure 55

Systemic Events, by Maximum Severity, Within 7 Days After Each Dose – Safety Population – Stage 1, 2 Dose, 21 Days Apart – 65-85 Years of Age – BNT162b2




Note: Severity was not collected for use of antipyretic or pain medication.
Note: Number above each bar denotes percentage of participants reporting the event with any severity.

Figure 56




Note: Dot presents individual antibody levels.
Note: Number within each bar denotes geometric mean.

Figure 57




Note: Dot presents individual antibody levels.
Note: Number within each bar denotes geometric mean.

Figure 58




Note: Dot presents individual antibody levels.
Note: Number within each bar denotes geometric mean.

Figure 59



Note: Dot presents individual antibody levels.
Note: Number within each bar denotes geometric mean.

Figure 60







Figure 61

64/155

Figure 62






Figure 64




Figure 65





Figure 66






Figure 68






Figure 69



72/155

Figure 70






Figure 71

74/155




Figure 71 (continued)

Figure 72






Figure 73



77/155

Figure 74



78/155

Figure 75




Figure 76





Figure 77



81/155

Figure 78




Figure 79




Figure 80




Figure 81




Figure 82




Figure 83




Figure 84




Figure 85




Figure 86




Figure 87




Figure 88




Figure 89




Figure 90




Figure 91




Figure 92




Figure 93




Figure 94




Figure 95




Figure 96




Figure 97




Figure 98




Figure 99





Figure 100



104/155






Figure 101

Figure 102



106/155

Figure 103



107/155




Figure 104

108/155






Figure 105

Figure 106



110/155

Figure 107



111/155





Figure 108

Figure 109



113/155




Figure 110




Figure 111

Figure 112

a





Figure 112

b



c




Figure 113




Figure 114





Figure 115

a



b




Figure 115

C




Figure 115

d




Figure 116

a




Figure 116




Figure 117




Figure 118





Figure 119



128/155

Figure 120




Figure 120

B




Figure 120






Figure 121

A Younger participants aged 18-55 years



B Older participants aged 65-85 years



132/155




Figure 122




Figure 123

Figure 124





Figure 125






Figure 126

137/155




Figure 127

Figure 128





Figure 129



140/155





Figure 130

Figure 131



142/155





Figure 132

Figure 133



144/155





Figure 134

Figure 135



146/155






Figure 136

Figure 137








Figure 139

Figure 140





Figure 141



152/155





Figure 142

Figure 143

IHC-ISH, modRNA-V9, draining LN, 6h, T20-0148






Figure 144




Figure 145